Robert Bosch Gesellschaft fuer medizinische Forschung mbH

Research activity centers on the detection of cardiotoxicity in oncology patients receiving anthracycline-based antineoplastic therapy, with attention to early myocardial damage associated with cancer treatment.

• Anthracycline-related cardiotoxicity
• Oncology patient cardiac monitoring
• Myocardial injury detection

The clinical focus includes identifying cardiac complications linked to routine cancer therapy and supporting safer management of patients exposed to anthracyclines.